Gniazdowska B, Ruëff F, Przybilla B
Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum Innenstadt der Ludwig-Maximilians-Universität, Munich, Germany.
Contact Dermatitis. 1999 Feb;40(2):63-5. doi: 10.1111/j.1600-0536.1999.tb05992.x.
Several non-steroidal anti-inflammatory drugs (NSAIDs) are available for topical treatment of acute soft tissue trauma or degenerative musculoskeletal disorders; the NSAID bufexamac is mainly used for therapy of chronic inflammatory skin diseases. In order to assess the occurrence of contact allergy to NSAIDs in 371 consecutive patients presenting for diagnosis of presumed contact allergy, patch tests were performed with a standard series and additionally with a series of NSAIDs, comprising acetylsalicylic acid, bufexamac, diclofenac, etofenamate, felbinac, flufenamic acid, ibuprofen, indomethacin, and piroxicam. 17 individuals (4.6%) exhibited delayed hypersensitivity to one of the NSAID preparations: 12 patients (3.2%) had patch test reactions to bufexamac, 2 (0.5%) to etofenamate, 2 (0.5%) to indomethacin, and 1 patient (0.3%) to flufenamic acid. These patch test results corresponded well to the individual history in 11 individuals (including 10 patients with reactions to bufexamac), and in 2 patients the clinical relevance of the reactions was probable. In view of the high frequency of allergic contact reactions to bufexamac, we propose to test this drug particularly in patients with atopic eczema or other chronic eczematous diseases.
有几种非甾体抗炎药（NSAIDs）可用于急性软组织创伤或退行性肌肉骨骼疾病的局部治疗；NSAID布非他命主要用于慢性炎症性皮肤病的治疗。为了评估371例连续前来诊断疑似接触性过敏的患者中对NSAIDs发生接触性过敏的情况，进行了标准系列斑贴试验，此外还进行了一系列NSAIDs的斑贴试验，包括阿司匹林、布非他命、双氯芬酸、依托芬那酯、非布索坦、氟芬那酸、布洛芬、吲哚美辛和吡罗昔康。17人（4.6%）对其中一种NSAID制剂表现出迟发型超敏反应：12例患者（3.2%）对布非他命斑贴试验有反应，2例（0.5%）对依托芬那酯有反应，2例（0.5%）对吲哚美辛有反应，1例患者（0.3%）对氟芬那酸有反应。这些斑贴试验结果与11人的个人病史（包括10例对布非他命有反应的患者）非常吻合，2例患者反应的临床相关性可能存在。鉴于对布非他命发生过敏性接触反应的频率较高，我们建议特别对特应性湿疹或其他慢性湿疹性疾病患者进行该药物的检测。
